Oxidative Stress Mediates through Apoptosis the Anticancer Effect of Phospho-Nonsteroidal Anti-Inflammatory Drugs: Implications for the Role of Oxidative Stress in the Action of Anticancer Agents

Yu Sun, Liquan Huang, Gerardo G. Mackenzie, and Basil Rigas

Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York

Received May 9, 2011; accepted June 3, 2011

ABSTRACT

We assessed the relationship between oxidative stress, cytokinetic parameters, and tumor growth in response to novel phospho-nonsteroidal anti-inflammatory drugs (NSAIDs), agents with significant anticancer effects in preclinical models. Compared with controls, in SW480 colon and MCF-7 breast cancer cells, phospho-sulfonid, phospho-aspirin, phospho-flurbiprofen, and phospho-ibuprofen (P-I) increased the levels of reactive oxygen and nitrogen species (RONS) and decreased GSH levels and thiorodoxin reductase activity, whereas the conventional chemotherapeutic drugs (CCDs), 5-fluorouracil (5-FU), irinotecan, oxaliplatin, doxorubicin, paclitaxel, and vincristine, did not. In both cell lines, phospho-NSAIDs induced apoptosis and inhibited cell proliferation much more potently than CCDs. We then treated nude mice bearing SW480 xenografts with P-I or 5-FU that had an opposite effect on RONS in vitro. Compared with controls, P-I markedly suppressed xenograft growth, induced apoptosis in the xenografts (8.9 ± 2.7 versus 19.5 ± 3.0), inhibited cell proliferation (52.6 ± 5.58 versus 25.8 ± 7.71), and increased urinary F2-isoprostane levels (10.7 ± 3.3 versus 17.9 ± 2.2 ng/mg creatinine, a marker of oxidative stress); all differences were statistically significant. 5-FU’s effects on tumor growth, apoptosis, proliferation, and F2-isoprostane were not statistically significant. F2-isoprostane levels correlated with the induction of apoptosis and the inhibition of cell growth. P-I induced oxidative stress only in the tumors, and its apoptotic effect was restricted to xenografts. Our data show that phospho-NSAIDs act against cancer through a mechanism distinct from that of various CCDs, underscore the critical role of oxidative stress in their effect, and indicate that pathways leading to oxidative stress may be useful targets for anticancer strategies.

Introduction

NSAIDs have emerged as significant chemopreventive agents against several cancers (Crew and Neugut, 2006; Baron, 2009). Their limited efficacy and appreciable side effects have motivated several groups to modify the structure of NSAIDs to enhance their efficacy and/or decrease their side effects. Such modifications have centered on covalently modifying NSAIDs at their –COOH moiety, which is a structural feature of nearly all of them (Piazza et al., 2009). We have worked with two classes of modified NSAIDs, namely nitric oxide-donating NSAIDs and phospho-NSAIDs; the chemopreventive efficacy of both has been demonstrated in preclinical models (Rigas, 2007; Zhao et al., 2009; Huang et al., 2010; Mackenzie et al., 2010).

Significant work in the last decade has attempted to unravel the mechanism of action of modified NSAIDs. Modulation by modified NSAIDs of several signaling pathways, some of them critical to the survival of the neoplastic cell, has been reported to mediate their chemopreventive effect (Rigas, 2007). It seems that although such changes are important, none of them represents a dominant mechanism or is sufficient to explain their efficacy. Our recent work suggests as a potentially unifying mechanistic theme the induction of oxi-
dative stress by modified NSAIDs, upon which most or all of the critical signaling changes depend. In particular, when we mapped the temporal sequence of cell signaling changes in response to nitric oxide-aspirin it was clear that increased intracellular levels of reactive oxygen and nitrogen species (RONS) preceded the activation of signaling pathways controlling proliferation and apoptosis (Sun and Rigas, 2008). We also noted that the pathways affected by modified NSAIDs were redox-sensitive. Furthermore, we have demonstrated that pretreatment of cells with antioxidant agents, such as N-acetyl-cysteine (NAC), abrogates the growth inhibitory effect of phospho-NSAIDs (Sun and Rigas, 2008; Zhao et al., 2009; Huang et al., 2010; Mackenzie et al., 2010).

Oxidative stress represents an irreversible state in which the intracellular level of RONS is increased. The idea that particularly high RONS levels may contribute to the antineoplastic effect of several agents has been gaining acceptance (Rigas and Sun, 2008). Given the evidence that phospho-NSAIDs may share as a critical proximal event in their mechanism of action the induction of oxidative stress, we undertook a systematic evaluation of this question. To this end, we studied four structurally diverse phospho-NSAIDs and determined in human colon and breast cancer cell lines the relationship between the induction of oxidative stress and cell growth inhibition. As controls, we evaluated the effect of several conventional chemotherapeutic drugs (CCDs) that are used clinically in the treatment of breast or colon cancer. The mechanism of the anticancer effect of CCDs varies. However, there is a common recognition that oxidative stress is important in modulating such effect and this biochemical property can be exploited for therapeutic benefits (Trachootham et al., 2009).

The cellular levels of RONS are determined by their rate production and also the antioxidant defense mechanism, notably the thioredoxin (Trx) system (Holmgren et al., 2005; Arnór, 2009; Meyer et al., 2009; Ciru and Aw, 2010) and GSH, the most important chemical antioxidant agent in mammalian cells (Diaz Vivancos et al., 2010; Jones and Go, 2010). Indeed, we have reported that some of our study compounds suppress the cellular levels of GSH and the Trx system mediates, to a significant extent, their proapoptotic effect (Sun and Rigas, 2008). These compounds convert Trx-1 to its oxidized (inactive) form by suppressing the activity of thioredoxin reductase (TrxR), the enzyme that reduces oxidized Trx-1 (Sun and Rigas, 2008).

Here, we demonstrate that in both breast and colon cancer cell lines phospho-NSAIDs induce oxidative stress, which is of greater intensity compared with that induced by CCDs. In both cases, oxidative stress is accompanied by reduced GSH levels and TrxR activity. We also show that oxidative stress correlates with the induction of apoptosis both in vitro and in vivo, paralleling their antitumor efficacy.

Materials and Methods

Reagents. We obtained all conventional drugs from Sigma-Aldrich (St. Louis, MO). DCFDA, annexin V, propidium iodide (PI), and JC-1 were from Invitrogen (Carlsbad, CA). BrdU and anti-BrdU-FITC were from BD Bioscience (San Jose, CA). Phospho-sulindac (P-S; OXT-328), phosphor-aspirin (P-A; MDC-43), phosphor-flurbiprofen (P-F; MDC-813), and phosphor-ibuprofen (P-I; MDC-917) were gifts from Medicon Pharmaceuticals, Inc. (Stony Brook, NY). All drugs were dissolved in dimethyl sulfoxide as 100 mM stock solution and diluted to their final concentration in cell culture media. Phospho-NSAIDs in general are stable at 4°C for more than 1 year (Xie et al., 2011 and data not shown).

Cell Culture. The SW480 human colon cancer cells, established from a lymph node metastasis from a primary adenocarcinoma of the colon (Leibovitz et al., 1976), incubated in 5% CO2 at 37°C, were grown in RPMI medium containing 10% fetal bovine serum and antibiotics and MCF-7 human breast cancer cells (McGrath et al., 1974) in Eagle’s minimum essential medium (American Type Culture Collection, Manassas, VA) containing 0.01 mg/ml human insulin, 10% fetal bovine serum, and antibiotics. The MCF-7 cells are human breast epithelial adenocarcinoma cells derived from the metastatic pleural effusion of a patient with breast adenocarcinoma. This cell line retains several characteristics of differentiated mammary epithelium including the ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes (Huguet et al., 1994). Both cell lines were obtained from the American Type Culture Collection.

Determination of RONS by FACSscalibur. After treatment with the test drug in six-well plates (0.3 x 10⁶ cells/well) for 1 h, cells were trypsinized and stained with 10 μM DCFDA for 30 min at 37°C, and their fluorescence intensity was analyzed with a FACSscalibur (BD Bioscience).

Determination of Cell Death by Annexin V and PI Staining. After cells were treated with the test drugs in 12-well plates for 16 h, all cell populations (suspended and attached) were collected and stained with annexin V-FITC (100XX dilution) and PI (0.5 μg/ml) for 15 min. Annexin V-FITC and PI fluorescence intensities were analyzed with a FACSscalibur. Annexin V(+)PI(−) cells are early apoptotic cells; annexin V(+)PI(+) cells are late apoptotic cells (i.e., they have undergone secondary necrosis); and annexin V(−)PI(+) cells are necrotic.

Determination of Mitochondrial Transmembrane Potential by JC-1 Staining. To determine the mitochondrial transmembrane potential (ΔΨm), after treatment with the test drugs for 3 h, cells were trypsinized and stained with 5 μM JC-1 for 30 min at 37°C and their fluorescence intensity was analyzed with a FACSscalibur.

Determination of Proliferation Using BrdU Staining. Cells were treated with the test drugs for 16 h. Before harvesting them, BrdU was added directly to the culture medium to a final concentration of 10 μM. All cell populations (suspended and attached) were incubated in the CO2 incubator for 30 min at 37°C, harvested, and fixed in 70% ethanol for 30 min on ice. DNA was denatured by incubating the cells with 2 N HCl/Triton X-100 for 30 min, followed by neutralization in 0.1 M Na2B4O7/10H2O. After 30 min of incubation with 20 μl of anti-BrdU-FITC per 10⁶ cells, cells were washed and resuspended in PBS containing 5 μg/ml PI. Cell fluorescence intensities were analyzed with a FACSscalibur.

Thioredoxin Reductase Activity Assay. After treatment with the test drugs for 3 h, cells were lysed in RIPA lysis buffer (Sigma-Aldrich), and TrxR activity was determined in the protein lysate of the test drugs for 1 h. The SW480 human colon cancer cells, established from a lymph node metastasis from a primary adenocarcinoma of the colon (Leibovitz et al., 1976), incubated in 5% CO2 at 37°C, were grown in RPMI medium containing 10% fetal bovine serum and antibiotics and MCF-7 human breast cancer cells (McGrath et al., 1974) in Eagle’s minimum essential medium (American Type Culture Collection, Manassas, VA) containing 0.01 mg/ml human insulin, 10% fetal bovine serum, and antibiotics. The MCF-7 cells are human breast epithelial adenocarcinoma cells derived from the metastatic pleural effusion of a patient with breast adenocarcinoma. This cell line retains several characteristics of differentiated mammary epithelium including the ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes (Huguet et al., 1994). Both cell lines were obtained from the American Type Culture Collection.
Oxidative Stress Mediates the Effect of Phospho-NSAIDs

All study compounds inhibited the growth of SW480 and MCF-7 cells (Table 1). SW480 and MCF-7 cells were incubated for 1 h with each of the test compounds at the respective $1.5 \times IC_{50}$ values for cell growth. Intracellular RONS were detected using DCFDA (Fig. 1), a molecular probe that detects $>10$ individual reactive species (Bass et al., 1983; LeBel et al., 1992). We also determined the intracellular levels of GSH and the activity of TrxR (Fig. 2).

Compared with controls, in SW480 cells RONS levels increased 5.3-fold ($p = 0.06$) in response to phospho-NSAIDs and only marginally (1.4-fold, $p = 0.31$) in response to CCDs (Table 1). This effect was accompanied by 1) reduced GSH levels: 55% by phospho-NSAIDs ($p < 0.0001$) and 9.4% ($p = 0.003$) by CCDs; and 2) reduced TrxR activity: 33% ($p = 0.02$) by phospho-NSAIDs and no change by CCDs (Fig. 2 and Table 1). In MCF-7 breast cancer cells we obtained similar results (Figs. 1 and 2; Table 2). Specifically, compared with controls, phospho-NSAIDs increased RONS levels 3.8-fold ($p = 0.04$) and reduced GSH levels by 39.8% ($p < 0.0001$) and TrxR activity by 41% ($p = 0.059$). CCDs had no statistically significant effects on these parameters: RONS levels were increased 1.7-fold ($p = 0.07$), GSH levels were reduced by only 9.1% ($p = 0.16$), and TrxR activity did not change. It is noteworthy that in both SW480 and MCF-7 cell lines, compared with CCDs, phospho-NSAIDs induced significantly more RONS (3.8- and 2.1-fold, respectively; $p < 0.05$ for both), reduced GSH levels 5.9- and 4.4-fold, respectively ($p < 0.001$ for both), and suppressed TrxR activity whereas CCDs failed to have any effect on it.

Phospho-NSAIDs Induce Apoptosis More Potently than CCDs in Colon and Breast Cancer Cells. We evaluated the effect of both phospho-NSAIDs and CCDs on cyto-kinetics of the two cell lines. We determined apoptosis using annexin V staining and $\Delta \Psi_m$. Mitochondria, the main source of RONS, are central to cell survival and death (Circu and Aw, 2010). Collapse of $\Delta \Psi_m$, which maintains their physiological function such as ATP production, induces cytochrome c release and activates downstream cell death signaling. To determine $\Delta \Psi_m$ we used the molecular marker JC-1; increased JC-1 green fluorescence indicates decreased $\Delta \Psi_m$. We also determined the effect of phospho-NSAIDs and CCDs on cell proliferation by using BrdU incorporation. There is evidence that, under certain conditions, the induction of

<table>
<thead>
<tr>
<th>Treatment</th>
<th>IC_{50}</th>
<th>DCFDA</th>
<th>GSH</th>
<th>TrxR</th>
<th>Annexin V</th>
<th>JC-1</th>
<th>BrdU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>23.7 ± 3.1</td>
<td>43.2</td>
<td>48.8</td>
<td>1.33</td>
<td>21.8</td>
<td>183</td>
<td>1.2</td>
</tr>
<tr>
<td>P-A</td>
<td>37 ± 1.6</td>
<td>98.5</td>
<td>38.7</td>
<td>1.18</td>
<td>44.6</td>
<td>717</td>
<td>1.3</td>
</tr>
<tr>
<td>P-S</td>
<td>65 ± 4.3</td>
<td>170.6</td>
<td>45.9</td>
<td>1.42</td>
<td>89.9</td>
<td>1295</td>
<td>6.0</td>
</tr>
<tr>
<td>P-F</td>
<td>79 ± 2.9</td>
<td>88.1</td>
<td>46.5</td>
<td>2.04</td>
<td>67.3</td>
<td>235</td>
<td>12.7</td>
</tr>
<tr>
<td>Mean ± S.E.M.</td>
<td>125.2 ± 36.9</td>
<td>45.0 ± 2.2</td>
<td>1.5 ± 0.2</td>
<td>55.9 ± 14.7</td>
<td>607.5 ± 258.8</td>
<td>5.3 ± 2.7***</td>
<td></td>
</tr>
<tr>
<td>5-FU</td>
<td>173 ± 14.2</td>
<td>23.01</td>
<td>94.2</td>
<td>2.54</td>
<td>4.9</td>
<td>145.5</td>
<td>28.5</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>61 ± 5.9</td>
<td>21.6</td>
<td>92.8</td>
<td>2.24</td>
<td>5.2</td>
<td>163</td>
<td>19.9</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>167 ± 12.0</td>
<td>33</td>
<td>93.9</td>
<td>2.78</td>
<td>12.1</td>
<td>217</td>
<td>29.1</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>135 ± 14.9</td>
<td>23.4</td>
<td>87.6</td>
<td>2.35</td>
<td>8.1</td>
<td>160</td>
<td>15.6</td>
</tr>
<tr>
<td>Vinorelvin</td>
<td>55 ± 7.4</td>
<td>65.6</td>
<td>84.6</td>
<td>1.88</td>
<td>7.7</td>
<td>251</td>
<td>14.2</td>
</tr>
<tr>
<td>Mean ± S.E.M.</td>
<td>33.3 ± 8.3</td>
<td>90.6 ± 1.5***</td>
<td>2.4 ± 0.15</td>
<td>7.6 ± 1.3*</td>
<td>187.3 ± 20.1*</td>
<td>21.5 ± 3.2*</td>
<td></td>
</tr>
</tbody>
</table>

* $n \geq 3$ different experiments, each done in triplicate.
† Compared with control: $P = 0.06$.
‡ Compared with control: $P = 0.063$.
§ $P < 0.05$; **$P < 0.01$; ***$P < 0.001$ compared with control.
RONS could inhibit cell proliferation (Chan et al., 2009; Sarsour et al., 2009; Visconti and Grieco, 2009).

As shown in Fig. 3 and Table 1 in SW480 cells phospho-NSAIDs induced apoptosis strongly, increasing it 13-fold over controls \((p < 0.01)\), whereas CCDs doubled, an effect that was not statistically significant \((p = 0.15)\). Apoptosis includes all annexin V\((+)\) cells, i.e., those showing early [annexin V\((+)/PI(-)] and late [annexin V\((+)/PI(+)\)] apoptosis. JC-1 fluorescence also changed in the same manner: phospho-NSAIDs induced apoptosis strongly, increasing it 4.6-fold over controls \((p < 0.05)\), whereas the change by CCDs was marginal and statistically not significant \((p = 0.66)\). In MCF-7 cells the results were similar (Fig. 4 and Table 2). Specifically, compared with control, phospho-NSAIDs increased annexin V\((+)\) cells 10-fold \((p < 0.01)\) and JC-1 green fluorescence 4.3-fold \((p < 0.05)\), whereas CCDs failed to change these parameters in a statistically significant way. When the percentages of annexin V\((+)\) cells and the JC-1 fluorescence intensity of the phospho-NSAID group were compared with those of the CCDs group both were significantly higher (7.4- and 3.2-fold, respectively, in SW480 cells and 6.5- and 4.1-fold, respectively, in MCF-7 cells; \(p < 0.01\) for all).

Finally, pretreating these cells with the antioxidant NAC restored RONS to baseline but TrxR activity remained unaffected (Fig. 5). In addition, NAC suppressed the induction of apoptosis by these compounds, indicating that RONS are the agents mediating cell death.

**Phospho-NSAIDs and CCDs Inhibit Proliferation in Colon and Breast Cancer Cells.** Both groups of study compounds inhibited cell proliferation. As shown in Fig. 3C...
and Table 1, in SW480 cells phospho-NSAIDs inhibited proliferation by 84% \((p < 0.001)\) and CCDs by 35% \((p < 0.03)\). The effect of phospho-NSAIDs was significantly stronger than that of CCDs \((p < 0.001)\). In MCF-7 cells phospho-NSAIDs inhibited proliferation by 82% \((p < 0.001)\) and CCDs by 76% \((p < 0.001)\), but the difference between these two groups was not statistically significant (Fig. 4C and Table 2).

A Phospho-NSAID (but Not a CCD) Induces Oxidative Stress in Tumor Xenografts: Association between Oxidative Stress and Apoptosis. Quantitatively the most pronounced cytokinetic difference between phospho-NSAIDs and CCDs in cultured cells was observed in the induction of RONS and apoptosis. To assess whether this difference also occurs in vivo, we treated with P-I or 5-FU nude mice bearing SW480 xenografts. These two compounds are representative of the phospho-NSAIDs and CCDs, which had an opposite effect on RONS levels in vitro. To assess whether this difference also occurs in vivo, we treated with P-I or 5-FU nude mice bearing SW480 xenografts. These two compounds are representative of the phospho-NSAIDs and CCDs, which had an opposite effect on RONS levels in vitro. The level of urinary F2-isoprostane was used as a marker of oxidative stress (Basu, 2008; Tacconelli et al., 2010). We used two control groups: 1) nude mice with xenografts that were treated with vehicle, and 2) nude mice without xenografts that were treated with P-I or 5-FU.

As expected, P-I markedly suppressed the growth of the xenografts, essentially achieving tumor stasis (Fig. 6A); the difference in tumor size from control became statistically significant on day 12 and continued to be so to the end of the study on day 22 \((p = 0.03–0.04)\). In contrast, 5-FU had only a modest inhibitory effect on the growth of the xenografts, which never reached statistical significance (e.g., \(p = 0.17\)

### Table 2

Values of parameters determined in MCF-7 cells treated with the study compounds

<table>
<thead>
<tr>
<th>MCF-7</th>
<th>IC50(a)</th>
<th>DCFDA</th>
<th>GSH</th>
<th>TrxR</th>
<th>Annexin V(+)</th>
<th>JC-1</th>
<th>BrdU</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(\mu M)</td>
<td>geometric mean</td>
<td>% control</td>
<td>(\mu mol \cdot min^{-1} \cdot ml^{-1})</td>
<td>% total</td>
<td>geometric mean</td>
<td>% total</td>
</tr>
<tr>
<td>Control</td>
<td>28.9 ± 2.1</td>
<td>100 ± 0</td>
<td>9.3 ± 0.4</td>
<td>7.8 ± 0.3</td>
<td>146 ± 8.2</td>
<td>19.9 ± 1.6</td>
<td></td>
</tr>
<tr>
<td>P-A</td>
<td>23 ± 1.6</td>
<td>45.2</td>
<td>58.3</td>
<td>9.11</td>
<td>66.4</td>
<td>330</td>
<td>3.26</td>
</tr>
<tr>
<td>P-S</td>
<td>62 ± 4.4</td>
<td>110.8</td>
<td>64.4</td>
<td>4.56</td>
<td>54.1</td>
<td>566</td>
<td>3.28</td>
</tr>
<tr>
<td>P-F</td>
<td>65 ± 5.8</td>
<td>164.3</td>
<td>57.6</td>
<td>3.1</td>
<td>96.7</td>
<td>747</td>
<td>3.47</td>
</tr>
<tr>
<td>P-I</td>
<td>79 ± 5.6</td>
<td>119.9</td>
<td>60.5</td>
<td>5.34</td>
<td>97.9</td>
<td>845</td>
<td>4.18</td>
</tr>
<tr>
<td>Mean ± S.E.M.</td>
<td>110.1 ± 24.6(b)</td>
<td>60.2 ± 1.5(b)</td>
<td>5.5 ± 1.3(b)</td>
<td>78.8 ± 11.0(b)</td>
<td>622 ± 113.3(b)</td>
<td>3.5 ± 0.2(b)</td>
<td></td>
</tr>
<tr>
<td>5-FU</td>
<td>283 ± 12.4</td>
<td>35.3</td>
<td>95.3</td>
<td>9.6</td>
<td>7.7</td>
<td>135</td>
<td>3.29</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>58 ± 3.9</td>
<td>39.1</td>
<td>95.3</td>
<td>7.34</td>
<td>9.1</td>
<td>166</td>
<td>4.28</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>33 ± 4.7</td>
<td>69.2</td>
<td>96.9</td>
<td>10.71</td>
<td>14.2</td>
<td>135</td>
<td>5.11</td>
</tr>
<tr>
<td>Vincristine</td>
<td>37 ± 2.2</td>
<td>56.7</td>
<td>76.1</td>
<td>7.61</td>
<td>17.2</td>
<td>165</td>
<td>7.34</td>
</tr>
</tbody>
</table>

Mean ± S.E.M. | 50.1 ± 7.9 | 90.9 ± 4.9 | 8.8 ± 0.8 | 12.1 ± 2.2 | 150.3 ± 8.8 | 4.8 ± 1.0\(b\) |

\(a\) \(n \geq 3\) different experiments, each done in triplicate.

\(b\) Compared with control: \(P = 0.059\).

\(c\) Compared with control: \(P = 0.07\).

\(*P < 0.05; \**P < 0.01; \***P < 0.001\) compared with control.
day 22). P-I induced apoptosis in the xenografts, more than doubling the apoptosis index, compared with controls (controls/H11005 8.9/H11006 2.7; P-I-treated/H11005 19.5/H11006 3.0 (mean/S.E.M. for this and all subsequent values; \( p = 0.035 \); Fig. 6, B and E). However, no significant induction of apoptosis by 5-FU, was noted (\( p = 0.81 \)). In terms of cell proliferation (Fig. 6, B and E), P-I inhibited it by 51% (controls/H11005 52.6/H11006 5.58; P-I-treated/H11005 25.8/H11006 7.71; \( p = 0.025 \)), whereas the effect of 5-FU was not statistically significant (\( p = 0.25 \)).

The levels of urinary F2-isoprostane were significantly elevated in mice treated with P-I (Fig. 6C). On day 10, these levels were 10.7 ± 3.3 ng/mg creatinine in controls and 17.9 ± 2.2 ng/mg creatinine in the PI-treated group, representing a nearly 70% increase over controls (\( p < 0.05 \)). In contrast, 5-FU failed to significantly increase them (12.1 ± 0.7 ng/mg creatinine; \( p = 0.6 \)). To ensure that the source of F2-isoprostane was the xenografts, we determined F2-isoprostane levels in nude mice that had no xenografts but were treated with P-I or 5-FU following the same protocol. No appreciable change in F2-isoprostane levels was noted in any of the treated groups (Fig. 6C). Of interest, the urinary F2-isoprostane levels in all mice bearing xenografts (controls plus those treated with P-I or 5-FU) were positively associated with the number of apoptotic cells in the xenografts (\( r = 0.580, p < 0.05 \); Fig. 6D). However, no such correlation was observed between urinary F2-isoprostane levels and cell proliferation (Ki-67) (Supplemental Fig. 2). Finally, to determine the specificity of the effect of P-I on apoptosis and proliferation in the SW480 colon cancer xenografts, we determined the effect of P-I and 5-FU on proliferation and apoptosis of the colonic mucosa in nude mice without xenografts. Neither compound changed significantly either parameter (data not shown). There was a correlation between F2-isoprostane levels and tumor growth, which almost...
reached statistical significance ($p = 0.06$); this borderline level of significance may reflect our rather small sample size. These findings suggest a potential etiological connection between oxidative stress and the induction of apoptosis in tumor xenografts.

**Discussion**

Our data establish the induction of oxidative stress as an important mechanism of action of the novel phospho-NSAIDs. Furthermore, they indicate that the apoptotic death of cancer cells is an important consequence of oxidative stress such that it affects tumor growth, i.e., the intended therapeutic outcome of these compounds. These effects were not observed in response to CCDs, indicating a striking difference between these two groups of compounds.

We assessed the relationship between oxidative stress, cytokinetic parameters, and tumor growth in response to phospho-NSAIDs using structurally diverse compounds and two human cancer cell lines that represent two of the commonest human cancers, colon and breast, which differ significantly in both their biology and clinical behavior. The in vitro data were complemented by in vivo studies, all of which used as controls CCDs that are used to treat these two tumors. The sets of CCDs for breast and colon cancer are not identical, overlap-
Our study generated several important findings. First, the phospho-NSAIDs induced in both cell lines a state of oxidative stress. This is probably the result of increased production of RONS and a weakened RONS inactivation response, reflected in the suppressed cellular levels of GSH and TrxR, both critical determinants of a cell’s ability to contain RONS and the consequent cellular damage. Indeed, our prior detailed work with P-S, one of these compounds, has demonstrated that the thioredoxin system (of which TrxR is a pivotal component (Sun and Rigas, 2008; Mackenzie et al., 2011) mediates most of its growth inhibitory effect.

Second, oxidative stress in response to phospho-NSAIDs is accompanied by two consequential cytokinetic changes, the induction of apoptosis and the suppression of proliferation. The former is quantitatively more pronounced, and, as the study using the antioxidant NAC showed, it totally depends on RONS.

Third, the effects of phospho-NSAIDs are dramatically different from those of CCDs in both cell lines. In both cell lines, CCDs failed to induce oxidative stress, having marginal or no effects on GSH and TrxR. Their main cytokinetic effect was inhibition of proliferation, which seemed to be weaker than that by phospho-NSAIDs.

The animal studies confirmed the in vitro findings and provided an insight into the sequence of events that culminated in the anticancer effect, i.e., tumor growth inhibition. P-I, representing the phospho-NSAIDs, induced oxidative stress, but this occurred only in the tumor tissue and not in normal tissues: F2-isoprostane levels were increased in animals bearing xenografts but not in those without them. Similar to cultured cells, the state of oxidative stress was accompanied by the induction of apoptosis and inhibition of proliferation. However, F2-isoprostane levels correlated only with the induction of apoptosis and this effect led predominantly to the anticancer effect. It was interesting that P-I had no effect on proliferation or apoptosis in the normal colonic mucosa of mice without tumors, indicating the tissue specificity of the effect and its association with oxidative stress.

F2-isoprostane levels did not correlate significantly with the inhibition of proliferation (p = 0.08). The relationship between RONS and proliferation is unclear and at best not uniform. In some cases, RONS increase cell proliferation (Klaunig et al., 1998, 2010; Brown and Bicknell, 2001; Visconti and Grieco, 2009), although in others they inhibit it (Klaunig et al., 1998, 2010; Brown and Bicknell, 2001; Visconti and Grieco, 2009), although in others they inhibit it (Klaunig et al., 1998, 2010; Brown and Bicknell, 2001; Visconti and Grieco, 2009). The effect of phospho-NSAIDs on ΔΨm shows that they target mitochondria, inducing apoptosis.

In conclusion, our study underscores the potentially critical role of the induction of oxidative stress in the therapeutic effect of phospho-NSAIDs, highlights their striking difference from CCDs in this regard, and indicates that pathways leading to oxidative stress may be useful targets for anticancer strategies.

Authorship Contributions

Participated in research design: Sun, Huang, Mackenzie, and Rigas.
Conducted experiments: Sun, Huang, and Mackenzie.
Contributed new reagents or analytic tools: Rigas.
Performed data analysis: Sun, Huang, Mackenzie, and Rigas.
Wrote or contributed to the writing of the manuscript: Sun and Rigas.

References


**Address correspondence to:** Basil Rigas, Division of Cancer Prevention, Health Sciences Center, T-17 Room 080, Stony Brook, NY 11794-8173. E-mail: basil.rigas@stonybrook.edu

---

**Oxidative Stress Mediates the Effect of Phospho-NSAIDs**


